AllianceBernstein Portfolio holdings
AllianceBernstein (AB), formed in 2000 through the merger of Alliance Capital and Bernstein, is a global asset management firm headquartered in Nashville, Tennessee, managing over $759 billion in assets as of late 2024 for institutional investors, financial advisors, and individuals. Known for its research-driven approach, AB offers a diverse range of investment strategies, including equities, fixed income, alternatives, and multi-asset solutions, with a strong emphasis on active management and ESG (environmental, social, governance) integration. The firm, which relocated its headquarters from New York City to Nashville in 2021, operates globally with significant operations in New York, London, and Asia, leveraging its Bernstein Research arm for deep market insights. With a workforce of over 4,700 and a partnership structure led by CEO Seth Bernstein, AB combines a legacy of rigorous analysis with a modern focus on sustainable investing and client outcomes.
Top Buys
| 1 |
Stryker
SYK
|
+$1.67B |
| 2 |
Applied Materials
AMAT
|
+$1.04B |
| 3 |
McKesson
MCK
|
+$998M |
| 4 |
Microsoft
MSFT
|
+$858M |
| 5 |
Progressive
PGR
|
+$723M |
Top Sells
| 1 |
Arista Networks
ANET
|
+$1.29B |
| 2 |
Zoetis
ZTS
|
+$1.11B |
| 3 |
Costco
COST
|
+$1.03B |
| 4 |
Cameco
CCJ
|
+$593M |
| 5 |
Tractor Supply
TSCO
|
+$567M |
Sector Composition
| 1 | Technology | 30.31% |
| 2 | Financials | 11.88% |
| 3 | Healthcare | 11.43% |
| 4 | Consumer Discretionary | 10.56% |
| 5 | Communication Services | 10.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2576
Apellis Pharmaceuticals
APLS
$3.4B
| $553K | ﹤0.01% |
31,929
-12,983
| -29% | -$225K |
|
2577
Vir Biotechnology
VIR
$720M
| $552K | ﹤0.01% |
109,620
| – | – |
|
2578
iShares US Real Estate ETF
IYR
$3.6B
| $552K | ﹤0.01% |
5,829
-555
| -9% | -$52.6K |
|
2579
Aris Water Solutions
ARIS
$783M
| $552K | ﹤0.01% |
23,330
| – | – |
|
2580
EyePoint Pharmaceuticals
EYPT
$986M
| $551K | ﹤0.01% |
58,590
+7,700
| +15% | +$72.5K |
|
2581
Orthofix Medical
OFIX
$581M
| $551K | ﹤0.01% |
49,409
-48,470
| -50% | -$540K |
|
2582
Frontier Group Holdings
ULCC
$1.18B
| $550K | ﹤0.01% |
151,390
+117,410
| +346% | +$426K |
|
2583
Organogenesis Holdings
ORGO
$619M
| $549K | ﹤0.01% |
149,890
+13,860
| +10% | +$50.7K |
|
2584
Diamond Hill
DHIL
$383M
| $548K | ﹤0.01% |
3,773
+1,800
| +91% | +$262K |
|
|
SAGE
2585
DELISTED
Sage Therapeutics
SAGE
| $546K | ﹤0.01% |
59,900
| – | – |
|
|
NMAX
2586
Newsmax, Inc.
NMAX
$1.67B
| $545K | ﹤0.01% |
+36,000
| New | +$545K |
|
|
PKST
2587
Peakstone Realty Trust
PKST
$487M
| $544K | ﹤0.01% |
41,190
+1,400
| +4% | +$18.5K |
|
2588
Preformed Line Products
PLPC
$925M
| $543K | ﹤0.01% |
3,400
+1,400
| +70% | +$224K |
|
2589
Tango Therapeutics
TNGX
$770M
| $543K | ﹤0.01% |
106,010
+41,070
| +63% | +$210K |
|
2590
First Foundation Inc
FFWM
$490M
| $543K | ﹤0.01% |
106,390
-135,152
| -56% | -$689K |
|
2591
Arvinas
ARVN
$590M
| $543K | ﹤0.01% |
73,720
| – | – |
|
2592
Ennis
EBF
$464M
| $542K | ﹤0.01% |
29,906
-1,530
| -5% | -$27.8K |
|
2593
Spyre Therapeutics
SYRE
$1.01B
| $542K | ﹤0.01% |
36,230
| – | – |
|
2594
Enhabit
EHAB
$398M
| $541K | ﹤0.01% |
56,090
-400
| -0.7% | -$3.86K |
|
2595
Intrepid Potash
IPI
$379M
| $541K | ﹤0.01% |
15,130
+2,930
| +24% | +$105K |
|
2596
Semler Scientific
SMLR
$416M
| $540K | ﹤0.01% |
+13,930
| New | +$540K |
|
|
GB
2597
DELISTED
Global Blue Group Holding
GB
| $538K | ﹤0.01% |
+72,036
| New | +$538K |
|
2598
OptimizeRx
OPRX
$334M
| $538K | ﹤0.01% |
39,850
+12,800
| +47% | +$173K |
|
2599
Zegna
ZGN
$2.24B
| $538K | ﹤0.01% |
+62,900
| New | +$538K |
|
2600
Capital City Bank Group
CCBG
$735M
| $537K | ﹤0.01% |
13,654
| – | – |
|